SK 1899

Drug Profile

SK 1899

Latest Information Update: 12 Jan 2004

Price : $50

At a glance

  • Originator SK Chemicals
  • Class Antivirals
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Viral infections

Most Recent Events

  • 12 Jan 2004 No development reported - Preclinical for Viral infections in South Korea (PO)
  • 30 Aug 2001 A preclinical study has been added to the pharmacokinetics section
  • 08 May 2000 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top